CryoLife, Inc. (CRY) Given Consensus Recommendation of “Buy” by Brokerages
CryoLife, Inc. (NYSE:CRY) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.63.
CRY has been the topic of a number of recent analyst reports. BidaskClub downgraded CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research downgraded CryoLife from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Canaccord Genuity reissued a “buy” rating and issued a $25.00 price objective on shares of CryoLife in a research note on Monday.
CryoLife (NYSE:CRY) traded down 15.88% during trading on Wednesday, reaching $19.60. The company’s stock had a trading volume of 225,657 shares. The firm has a 50 day moving average price of $21.82 and a 200-day moving average price of $19.17. The stock has a market cap of $655.54 million, a price-to-earnings ratio of 57.65 and a beta of 0.92. CryoLife has a 52-week low of $14.02 and a 52-week high of $24.00.
CryoLife (NYSE:CRY) last announced its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.13 EPS. On average, analysts expect that CryoLife will post $0.43 earnings per share for the current year.
In other news, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the transaction, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 125,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares in the company, valued at $8,768,761.99. The disclosure for this sale can be found here. Insiders sold a total of 171,050 shares of company stock worth $3,769,825 over the last three months. 6.00% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the company. State of Alaska Department of Revenue raised its stake in CryoLife by 80.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after buying an additional 2,407 shares during the period. First Mercantile Trust Co. raised its stake in CryoLife by 5.6% during the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after buying an additional 291 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in CryoLife by 3.2% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 190 shares during the period. Mason Street Advisors LLC raised its stake in CryoLife by 7.4% during the 1st quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 438 shares during the period. Finally, Creative Planning raised its stake in CryoLife by 3.0% during the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after buying an additional 200 shares during the period. 68.44% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/cryolife-inc-cry-given-consensus-recommendation-of-buy-by-brokerages.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.